Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
Add more filters










Publication year range
1.
Ann Rheum Dis ; 71(12): 2051-4, 2012 Dec.
Article in English | MEDLINE | ID: mdl-22915616

ABSTRACT

BACKGROUND: Selective targeting of the cannabinoid receptors CB1 and CB2 by synthetic compounds has revealed opposing roles of both receptors in fibrosis. OBJECTIVES: To characterise the role of endogenous cannabinoids (endocannabinoids) and their predominant receptor in fibrosis. METHODS: The levels of endocannabinoids in mice were modulated by pharmacological or genetic inactivation of the enzyme fatty acid amide hydrolase (FAAH). The predominant receptor for endocannabinoids was determined by selective inhibition of either CB1 or CB2. The extent of fibrosis upon challenge with bleomycin was determined by quantification of dermal thickness, hydroxyproline content and myofibroblast counts. RESULTS: The expression of FAAH is decreased in systemic sclerosis fibroblasts. FAAH-deficient mice with strongly increased levels of endocannabinoids were more sensitive to bleomycin. Consistently, pharmacological inhibition of FAAH significantly exacerbated bleomycin-induced fibrosis. Inhibition of CB1 completely abrogated the profibrotic effects of FAAH inactivation. In contrast, inhibition of CB2 only modestly enhanced fibrosis, indicating that CB1 is the predominant receptor for endocannabinoids in experimental fibrosis. CONCLUSIONS: Increased levels of endocannabinoids induced by inactivation of FAAH worsen experimental fibrosis via activation of CB1. These findings highlight the profibrotic effects of endocannabinoids and suggest that CB1 maybe a more promising candidate for targeted treatments in fibrotic diseases than CB2.


Subject(s)
Amidohydrolases/genetics , Endocannabinoids/metabolism , Receptor, Cannabinoid, CB1/metabolism , Skin Diseases/metabolism , Skin Diseases/pathology , Amidohydrolases/metabolism , Animals , Antibiotics, Antineoplastic/toxicity , Bleomycin/toxicity , Female , Fibroblasts/metabolism , Fibroblasts/pathology , Fibrosis/chemically induced , Fibrosis/metabolism , Fibrosis/pathology , Gene Expression Regulation, Enzymologic/physiology , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Receptor, Cannabinoid, CB2/metabolism , Skin Diseases/chemically induced
2.
Arthritis Rheum ; 64(9): 3006-15, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22549363

ABSTRACT

OBJECTIVE: To investigate whether JAK-2 contributes to the pathologic activation of fibroblasts in patients with systemic sclerosis (SSc) and to evaluate the antifibrotic potential of JAK-2 inhibition for the treatment of SSc. METHODS: Activation of JAK-2 in human skin and in experimental fibrosis was determined by immunohistochemical analysis. JAK-2 signaling was inhibited by the selective JAK-2 inhibitor TG101209 or by small interfering RNA. Bleomycin-induced dermal fibrosis in mice and TSK-1 mice were used to evaluate the antifibrotic potential of specific JAK-2 inhibition in vivo. RESULTS: Increased activation of JAK-2 was detected in the skin of patients with SSc, particularly in fibroblasts. The activation of JAK-2 was dependent on transforming growth factor ß (TGFß) and persisted in cultured SSc fibroblasts. Inhibition of JAK-2 reduced basal collagen synthesis selectively in SSc fibroblasts but not in resting healthy dermal fibroblasts. Moreover, inhibition of JAK-2 prevented the stimulatory effects of TGFß on fibroblasts. Treatment with TG101209 not only prevented bleomycin-induced fibrosis but also effectively reduced skin fibrosis in TSK-1 mice. CONCLUSION: We demonstrated that JAK-2 is activated in a TGFß-dependent manner in SSc. Considering the potent antifibrotic effects of JAK-2 inhibition, our study might have direct translational implications, because inhibitors of JAK-2 are currently being evaluated in clinical trials for myeloproliferative disorders and would also be available for evaluation in patients with SSc.


Subject(s)
Janus Kinase 2/metabolism , Scleroderma, Systemic/metabolism , Transforming Growth Factor beta/metabolism , Adult , Aged , Animals , Enzyme Inhibitors/pharmacology , Female , Fibrosis/metabolism , Humans , Male , Mice , Middle Aged , Phosphorylation , Pyrimidines/pharmacology , Scleroderma, Systemic/pathology , Signal Transduction/drug effects , Skin/drug effects , Skin/metabolism , Skin/pathology , Sulfonamides/pharmacology
3.
Ann Rheum Dis ; 71(5): 785-9, 2012 May.
Article in English | MEDLINE | ID: mdl-22402139

ABSTRACT

OBJECTIVES: Tissue fibrosis is a leading cause of death in patients with systemic sclerosis (SSc). Effective antifibrotic treatments are not available. Here, the authors investigated inhibition of hedgehog signalling by targeting Smoothened (Smo) as a novel antifibrotic approach. METHODS: The activation status of the hedgehog pathway was assessed by immunohistochemistry for Gli transcription factors and by quantification of hedgehog target genes. Hedgehog signalling was inhibited by the selective inhibitor LDE223 and by small interfering RNA against Smo in the models of bleomycin-induced dermal fibrosis and in tight-skin-1 mice. RESULTS: Hedgehog signalling is activated in SSc and in murine models of SSc. Inhibition of Smo either by LDE223 or by small interfering RNA prevented dermal thickening, myofibroblast differentiation and accumulation of collagen upon challenge with bleomycin. Targeting Smo also exerted potent antifibrotic effects in tight-skin-1 mice and did prevent progression of fibrosis and induced regression of pre-established fibrosis. CONCLUSIONS: Inhibition of hedgehog signalling exerted potent antifibrotic effects in preclinical models of SSc in both preventive and therapeutic settings. These findings might have direct translational implications because inhibitors of Smo are already available and yielded promising results in initial clinical trials.


Subject(s)
Fibrosis , Receptors, G-Protein-Coupled/antagonists & inhibitors , Signal Transduction , Skin Diseases/pathology , Skin/pathology , Animals , Biphenyl Compounds/pharmacology , Bleomycin/toxicity , Disease Models, Animal , Drug Therapy, Combination , Fibrosis/metabolism , Fibrosis/pathology , Fibrosis/prevention & control , Mice , Mice, Inbred C57BL , Mice, Mutant Strains , RNA, Small Interfering/genetics , RNA, Small Interfering/pharmacology , Receptors, G-Protein-Coupled/biosynthesis , Receptors, G-Protein-Coupled/genetics , Scleroderma, Systemic/metabolism , Scleroderma, Systemic/pathology , Scleroderma, Systemic/prevention & control , Signal Transduction/drug effects , Skin/drug effects , Skin/metabolism , Skin Diseases/drug therapy , Skin Diseases/metabolism , Smoothened Receptor
4.
Nat Commun ; 3: 735, 2012 Mar 13.
Article in English | MEDLINE | ID: mdl-22415826

ABSTRACT

The transforming growth factor-ß (TGF-ß) signalling pathway is a key mediator of fibroblast activation that drives the aberrant synthesis of extracellular matrix in fibrotic diseases. Here we demonstrate a novel link between transforming growth factor-ß and the canonical Wnt pathway. TGF-ß stimulates canonical Wnt signalling in a p38-dependent manner by decreasing the expression of the Wnt antagonist Dickkopf-1. Tissue samples from human fibrotic diseases show enhanced expression of Wnt proteins and decreased expression of Dickkopf-1. Activation of the canonical Wnt pathway stimulates fibroblasts in vitro and induces fibrosis in vivo. Transgenic overexpression of Dickkopf-1 ameliorates skin fibrosis induced by constitutively active TGF-ß receptor type I signalling and also prevents fibrosis in other TGF-ß-dependent animal models. These findings demonstrate that canonical Wnt signalling is necessary for TGF-ß-mediated fibrosis and highlight a key role for the interaction of both pathways in the pathogenesis of fibrotic diseases.


Subject(s)
Fibrosis/pathology , Transforming Growth Factor beta/metabolism , Wnt Proteins/metabolism , Wnt Signaling Pathway , Adult , Animals , Cells, Cultured , Extracellular Matrix/metabolism , Female , Fibrosis/metabolism , Humans , Intercellular Signaling Peptides and Proteins/biosynthesis , Male , Mice , Mice, Transgenic , Middle Aged , RNA Interference , RNA, Small Interfering , Receptors, Transforming Growth Factor beta/metabolism , p38 Mitogen-Activated Protein Kinases/metabolism
5.
Arthritis Rheum ; 64(8): 2724-33, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22354771

ABSTRACT

OBJECTIVE: Hedgehog signaling not only plays crucial roles during human development but also has been implicated in the pathogenesis of several diseases in adults. The aim of the present study was to investigate the role of the hedgehog pathway in fibroblast activation in systemic sclerosis (SSc). METHODS: Activation of the hedgehog pathway was analyzed by immunohistochemistry and real-time polymerase chain reaction (PCR). The effects of sonic hedgehog (SHH) on collagen synthesis were analyzed by reporter assays, real-time PCR, and Sircol assays. Myofibroblast differentiation was assessed by quantification of α-smooth muscle actin and stress fiber staining. The role of hedgehog signaling in vivo was analyzed by adenoviral overexpression of SHH and using mice lacking 1 allele of the gene for inhibitory receptor Patched homolog 1 (Ptch(+/-) mice). RESULTS: SHH was overexpressed and resulted in activation of hedgehog signaling in patients with SSc, with accumulation of the transcription factors Gli-1 and Gli-2 and increased transcription of hedgehog target genes. Activation of hedgehog signaling induced an activated phenotype in cultured fibroblasts, with differentiation of resting fibroblasts into myofibroblasts and increased release of collagen. Adenoviral overexpression of SHH in the skin of mice was sufficient to induce skin fibrosis. Moreover, Ptch(+/-) mice with increased hedgehog signaling were more sensitive to bleomycin-induced dermal fibrosis. CONCLUSION: We demonstrated that the hedgehog pathway is activated in patients with SSc. Hedgehog signaling potently stimulates the release of collagen and myofibroblast differentiation in vitro and is sufficient to induce fibrosis in vivo. These findings identify the hedgehog cascade as a profibrotic pathway in SSc.


Subject(s)
Cell Differentiation/physiology , Fibroblasts/metabolism , Hedgehog Proteins/metabolism , Scleroderma, Systemic/metabolism , Signal Transduction/physiology , Skin/metabolism , Adult , Aged , Animals , Bleomycin/adverse effects , Case-Control Studies , Cells, Cultured , Collagen/metabolism , Female , Fibroblasts/pathology , Fibrosis/chemically induced , Humans , Male , Mice , Mice, Mutant Strains , Middle Aged , Models, Animal , Oncogene Proteins/metabolism , Patched Receptors , Patched-1 Receptor , Receptors, Cell Surface/genetics , Scleroderma, Systemic/pathology , Skin/pathology , Trans-Activators/metabolism , Wnt Signaling Pathway/physiology , Zinc Finger Protein GLI1
6.
Ann Rheum Dis ; 71(5): 737-45, 2012 May.
Article in English | MEDLINE | ID: mdl-22258492

ABSTRACT

OBJECTIVES: The hallmark of systemic sclerosis (SSc) is the accumulation of extracellular matrix proteins by pathologically activated fibroblasts. This study analysed the antifibrotic effects of the selective c-Jun N-terminal kinase (JNK) inhibitor, CC-930, which recently entered first clinical trials as a novel antifibrotic approach. METHODS: Phosphorylated c-Jun was detected by western blot and immunohistochemistry. The model of bleomycin-induced dermal fibrosis and the tight skin 1 (TSK1) mouse model were used to investigate the effects of CC-930 on the prevention of experimental fibrosis. The potential of CC-930 to induce regression of fibrosis was assessed in a modified model of established fibrosis. RESULTS: Transforming growth factor beta (TGFß) and platelet-derived growth factor (PDGF) activate JNK and stimulate the phosphorylation of its downstream target c-Jun. Incubation with CC-930 prevented the phosphorylation of c-Jun and reduced the stimulatory levels of these cytokines on the release of collagen. Inhibition of JNK prevented dermal thickening, myofibroblast differentiation and the accumulation of collagen in a dose-dependent manner in mice challenged with bleomycin and in TSK1 mice. In addition to the prevention of fibrosis, treatment with pharmacologically relevant doses of CC-930 also induced regression of established experimental fibrosis. CONCLUSIONS: These data identify JNK as a downstream mediator of the pro-fibrotic effects of of TGFß and PDGF in SSc fibroblasts. Selective inhibition of JNK by CC-930 exerted potent antifibrotic effects in vitro and in different models in vivo. JNK might thus be a novel molecular target for the treatment of fibrosis in SSc.


Subject(s)
Fibrosis/enzymology , Gene Targeting , JNK Mitogen-Activated Protein Kinases/metabolism , Scleroderma, Systemic/enzymology , Skin Diseases/enzymology , Adult , Aged , Animals , Bleomycin/toxicity , Cell Survival/drug effects , Cells, Cultured , Cyclohexanols/pharmacology , Cyclohexanols/therapeutic use , Disease Models, Animal , Extracellular Matrix Proteins/metabolism , Female , Fibrosis/genetics , Fibrosis/prevention & control , Humans , JNK Mitogen-Activated Protein Kinases/antagonists & inhibitors , JNK Mitogen-Activated Protein Kinases/genetics , Male , Mice , Mice, Inbred C57BL , Mice, Mutant Strains , Middle Aged , Phosphorylation , Purines/pharmacology , Purines/therapeutic use , Scleroderma, Systemic/genetics , Scleroderma, Systemic/pathology , Skin/drug effects , Skin/enzymology , Skin/pathology , Skin Diseases/chemically induced , Skin Diseases/genetics , Skin Diseases/pathology , Young Adult
7.
Ann Rheum Dis ; 71(3): 400-7, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22233602

ABSTRACT

BACKGROUND: Osteophyte formation is a common phenomenon in arthritis. Bone formation by endochondral ossification is considered a key pathophysiological process in the formation of osteophytes. OBJECTIVE: To examine the hypothesis that inhibition of smoothened (Smo), a key component of the hedgehog pathway inhibits osteophyte formation as the hedgehog pathway mediates endochondral ossification. METHODS: Arthritis was induced in 8-week-old C57/BL6 mice by serum transfer (K/BxN model). Mice were then treated by daily administration of either vehicle or LDE223, a specific small molecule inhibitor for Smo, over 2 weeks starting at the onset of disease. Clinical course of arthritis, histological and molecular changes of bone in the affected joints as well as systemic bone changes were assessed. RESULTS: Serum transfer-induced arthritis led to severe osteophyte formation within 2 weeks of onset. Blockade of Smo inhibited hedgehog signalling in vivo and also significantly inhibited osteophyte formation, whereas the clinical and histopathological signs of arthritis were not affected. Also, systemic bone mass did not change. Smo inhibitor particularly blocked the formation of hypertrophic chondrocytes and collagen type X expression. CONCLUSIONS: The data indicate that blockade of hedgehog signalling by targeting Smo specifically inhibits osteophyte formation in arthritis without affecting inflammation and without eliciting bone destruction at the local and systemic level. Blockade of Smo may thus be considered as a strategy to specifically influence the periosteal bone response in arthritis associated with bone apposition.


Subject(s)
Arthritis, Experimental/complications , Biphenyl Compounds/therapeutic use , Hedgehog Proteins/antagonists & inhibitors , Osteophyte/prevention & control , Animals , Arthritis, Experimental/drug therapy , Arthritis, Experimental/pathology , Biphenyl Compounds/pharmacology , Bone and Bones/metabolism , Cartilage, Articular/metabolism , Cell Differentiation/genetics , Chondrocytes/pathology , Drug Evaluation, Preclinical/methods , Hedgehog Proteins/physiology , Hypertrophy , Male , Mice , Mice, Inbred C57BL , Microscopy, Fluorescence , Osteoblasts/pathology , Osteophyte/etiology , Osteophyte/pathology , Periosteum/pathology , Receptors, G-Protein-Coupled/antagonists & inhibitors , Receptors, G-Protein-Coupled/physiology , Signal Transduction/drug effects , Signal Transduction/physiology , Smoothened Receptor , Up-Regulation/drug effects
8.
Arthritis Rheum ; 64(5): 1642-52, 2012 May.
Article in English | MEDLINE | ID: mdl-22139817

ABSTRACT

OBJECTIVE: To investigate whether c-Jun and c-Fos contribute to the pathologic activation of fibroblasts in systemic sclerosis (SSc) and to evaluate the antifibrotic potential of selective activator protein 1 (AP-1) inhibition. METHODS: Expression of c-Jun and c-Fos was determined by real-time polymerase chain reaction (PCR) and immunohistochemical analysis. Fibroblasts were stimulated with transforming growth factor ß (TGFß) and incubated with T-5224, a small-molecule inhibitor of AP-1, or were transfected with small interfering RNA (siRNA) duplexes against c-Jun and c-Fos. Collagen synthesis was quantified by real-time PCR and hydroxyproline assay. Differentiation of resting fibroblasts into myofibroblasts was assessed by staining for α-smooth muscle actin and stress fibers. The antifibrotic potential of T-5224 was evaluated in mouse models of dermal fibrosis induced by bleomycin or by adenoviral overexpression of a constitutively active TGFß receptor type I. RESULTS: Up-regulation of c-Jun and c-Fos was detected in mouse models of SSc and in the skin and dermal fibroblasts of patients with SSc. Stimulation of healthy fibroblasts with TGFß induced the expression of c-Jun and c-Fos. Treatment with T-5224 or nucleofection with siRNA directed against c-Jun and c-Fos abrogated the profibrotic effects of TGFß. T-5224 decreased the release of collagen selectively in SSc fibroblasts. T-5224 was well tolerated and prevented dermal fibrosis induced by bleomycin or by adenoviral activation of TGFß signaling. CONCLUSION: AP-1 is up-regulated in a TGFß-dependent manner in SSc. The selective AP-1 inhibitor T-5224 reduced collagen synthesis selectively in SSc fibroblasts and efficiently prevented the development of experimental dermal fibrosis. Thus, AP-1 might be a promising new molecular target for the treatment of SSc.


Subject(s)
Fibroblasts/metabolism , Fibrosis/prevention & control , JNK Mitogen-Activated Protein Kinases/genetics , Proto-Oncogene Proteins c-fos/genetics , Transcription Factor AP-1/antagonists & inhibitors , Transforming Growth Factor beta/pharmacology , Animals , Benzophenones/pharmacology , Bleomycin/toxicity , Cells, Cultured , Collagen/biosynthesis , Collagen/drug effects , Disease Models, Animal , Female , Fibroblasts/drug effects , Fibrosis/chemically induced , Fibrosis/pathology , Gene Expression/drug effects , Humans , Isoxazoles/pharmacology , JNK Mitogen-Activated Protein Kinases/metabolism , Male , Mice , Proto-Oncogene Proteins c-fos/metabolism , RNA, Small Interfering/genetics , Scleroderma, Systemic/genetics , Scleroderma, Systemic/metabolism , Scleroderma, Systemic/pathology , Signal Transduction/drug effects , Transcription Factor AP-1/metabolism , Transfection , Up-Regulation/drug effects
9.
J Exp Med ; 208(5): 961-72, 2011 May 09.
Article in English | MEDLINE | ID: mdl-21518801

ABSTRACT

Vascular damage and platelet activation are associated with tissue remodeling in diseases such as systemic sclerosis, but the molecular mechanisms underlying this association have not been identified. In this study, we show that serotonin (5-hydroxytryptamine [5-HT]) stored in platelets strongly induces extracellular matrix synthesis in interstitial fibroblasts via activation of 5-HT(2B) receptors (5-HT(2B)) in a transforming growth factor ß (TGF-ß)-dependent manner. Dermal fibrosis was reduced in 5-HT(2B)(-/-) mice using both inducible and genetic models of fibrosis. Pharmacologic inactivation of 5-HT(2B) also effectively prevented the onset of experimental fibrosis and ameliorated established fibrosis. Moreover, inhibition of platelet activation prevented fibrosis in different models of skin fibrosis. Consistently, mice deficient for TPH1, the rate-limiting enzyme for 5-HT production outside the central nervous system, showed reduced experimental skin fibrosis. These findings suggest that 5-HT/5-HT(2B) signaling links vascular damage and platelet activation to tissue remodeling and identify 5-HT(2B) as a novel therapeutic target to treat fibrotic diseases.


Subject(s)
Blood Platelets/metabolism , Extracellular Matrix/metabolism , Fibroblasts/metabolism , Scleroderma, Systemic/metabolism , Serotonin/metabolism , Animals , Blood Platelets/pathology , Disease Models, Animal , Extracellular Matrix/genetics , Extracellular Matrix/pathology , Fibroblasts/pathology , Fibrosis , Humans , Mice , Mice, Knockout , Platelet Activation/genetics , Receptor, Serotonin, 5-HT2B/genetics , Receptor, Serotonin, 5-HT2B/metabolism , Scleroderma, Systemic/genetics , Scleroderma, Systemic/pathology , Serotonin/genetics , Signal Transduction/genetics , Transforming Growth Factor beta/genetics , Transforming Growth Factor beta/metabolism
10.
Ann Rheum Dis ; 70(7): 1304-10, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21450749

ABSTRACT

BACKGROUND: Dermal fibroblasts from patients with systemic sclerosis (SSc) release excessive amounts of collagen resulting in tissue fibrosis. The molecular mechanisms underlying this pathological activation are incompletely understood. OBJECTIVE: To investigate whether Notch signalling contributes to the uncontrolled activation of fibroblasts in SSc. METHODS: Activation of the Notch pathway was assessed by immunohistochemistry or Western blot for the Notch intracellular domain and the Notch ligand Jagged-1 (Jag-1) and real-time PCR for the target gene hes-1. Differentiation of resting dermal fibroblasts into myofibroblasts was assessed by staining for α-smooth muscle actin. The synthesis of collagen was quantified by real-time PCR and Sircol assays. RESULTS: Notch signalling was activated in lesional skin of patients with SSc. The activation persisted in cultured dermal SSc fibroblasts. Stimulation of healthy dermal fibroblasts with recombinant human Jag-1-Fc chimera resulted in an SSc-like phenotype with increased release of collagen and differentiation of resting fibroblasts into myofibroblasts. Consistent with the selective activation of the Notch pathway in dermal SSc fibroblasts, DAPT or siRNA against Notch strongly reduced the basal collagen expression in SSc fibroblasts, but not in fibroblasts from healthy volunteers. CONCLUSION: It was shown that Notch signalling is activated in SSc and plays an important role in fibroblast activation and collagen release. Inhibition of Notch signalling might be an effective strategy to selectively prevent the aberrant activation of SSc fibroblasts.


Subject(s)
Collagen/metabolism , Fibroblasts/physiology , Receptors, Notch/physiology , Scleroderma, Systemic/pathology , Adult , Aged , Amyloid Precursor Protein Secretases/antagonists & inhibitors , Calcium-Binding Proteins/antagonists & inhibitors , Calcium-Binding Proteins/pharmacology , Cell Differentiation/drug effects , Cells, Cultured , Dipeptides/pharmacology , Dose-Response Relationship, Drug , Extracellular Matrix/drug effects , Female , Fibroblasts/drug effects , Fibroblasts/metabolism , Humans , Intercellular Signaling Peptides and Proteins/pharmacology , Jagged-1 Protein , Male , Membrane Proteins/antagonists & inhibitors , Membrane Proteins/pharmacology , Middle Aged , Myofibroblasts/pathology , Receptors, Notch/antagonists & inhibitors , Recombinant Proteins/pharmacology , Scleroderma, Systemic/metabolism , Serrate-Jagged Proteins , Signal Transduction/physiology , Skin/metabolism , Skin/pathology , Young Adult
11.
Arthritis Rheum ; 63(3): 800-9, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21360510

ABSTRACT

OBJECTIVE: The transcription factor STAT-4 has recently been identified as a genetic susceptibility factor in systemic sclerosis (SSc) and other autoimmune diseases. The aim of this study was to investigate the contribution of STAT-4 in the development of a fibrotic phenotype in 2 different mouse models of experimental dermal fibrosis. METHODS: STAT-4-deficient (stat4(-/-) ) mice and their wild-type littermates (stat4(+/+) ) were injected with bleomycin or NaCl. Infiltrating leukocytes, T cells, B cells, and monocytes were quantified in the lesional skin of stat4(-/-) and stat4(+/+) mice. Inflammatory and profibrotic cytokines were measured in sera and lesional skin samples from stat4(-/-) and stat4(+/+) mice. The outcome of mice lacking STAT-4 was also investigated in the tight skin 1 (TSK-1) mouse model. RESULTS: Stat4(-/-) mice were protected against bleomycin-induced dermal fibrosis, with a reduction in dermal thickening (mean ± SEM 65 ± 3% decrease; P = 0.03), hydroxyproline content (68 ± 5% decrease; P = 0.02), and myofibroblast counts (71 ± 6% decrease; P = 0.005). Moreover, the number of infiltrating leukocytes, especially T cells, was significantly decreased in the lesional skin of stat4(-/-) mice (mean ± SEM 63 ± 5% reduction in T cell count; P = 0.02). Stat4(-/-) mice also displayed decreased levels of inflammatory cytokines such as tumor necrosis factor α, interleukin-6 (IL-6), IL-2, and interferon-γ in lesional skin. Consistent with a primary role of STAT-4 in inflammation, STAT-4 deficiency did not ameliorate fibrosis in TSK-1 mice. CONCLUSION: The results of this study demonstrate that the transcription factor STAT-4 exerts potent profibrotic effects by controlling T cell activation and proliferation and cytokine release. These findings confirm the results of genetics studies on the role of STAT-4 in the development of SSc.


Subject(s)
STAT4 Transcription Factor/genetics , STAT4 Transcription Factor/immunology , Scleroderma, Systemic , Skin Diseases , Animals , Antibiotics, Antineoplastic , Bleomycin/toxicity , Cell Proliferation , Cytokines/immunology , Cytokines/metabolism , Dermis/immunology , Dermis/pathology , Disease Models, Animal , Female , Fibrosis/chemically induced , Fibrosis/immunology , Fibrosis/pathology , Genotype , Inflammation/genetics , Inflammation/immunology , Inflammation/pathology , Male , Mice , Mice, Inbred BALB C , Mice, Knockout , Phenotype , Scleroderma, Systemic/genetics , Scleroderma, Systemic/immunology , Scleroderma, Systemic/pathology , Skin Diseases/genetics , Skin Diseases/immunology , Skin Diseases/pathology , T-Lymphocytes/pathology
12.
Arthritis Rheum ; 63(5): 1396-404, 2011 May.
Article in English | MEDLINE | ID: mdl-21312186

ABSTRACT

OBJECTIVE: Tissue fibrosis caused by pathologic activation of fibroblasts with increased synthesis of extracellular matrix components is a major hallmark of systemic sclerosis (SSc). Notch signaling regulates tissue differentiation, and abnormal activation of Notch signaling has been implicated in the pathogenesis of various malignancies. The present study was undertaken to investigate the role of Notch signaling in SSc and to evaluate the therapeutic potential of Notch inhibition for the treatment of fibrosis. METHODS: Activation of the Notch pathways was analyzed by staining for the Notch intracellular domain (NICD) and quantification of levels of HES-1 messenger RNA. In the mouse model of bleomycin-induced dermal fibrosis and in tight skin 1 mice, Notch signaling was inhibited by the γ-secretase inhibitor DAPT and by overexpression of a Notch-1 antisense construct. RESULTS: Notch signaling was activated in SSc in vivo, with accumulation of the NICD and increased transcription of the target gene HES-1. Overexpression of a Notch antisense construct prevented bleomycin-induced fibrosis and hypodermal thickening in tight skin 1 mice. Potent antifibrotic effects were also obtained with DAPT treatment. In addition to prevention of fibrosis, targeting of Notch signaling resulted in almost complete regression of established experimental fibrosis. CONCLUSION: The present results demonstrate that pharmacologic as well as genetic inhibition of Notch signaling exerts potent antifibrotic effects in different murine models of SSc. These findings might have direct translational implications because different inhibitors of the γ-secretase complex are available and have yielded promising results in cancer trials.


Subject(s)
Fibroblasts/metabolism , Receptors, Notch/metabolism , Scleroderma, Systemic/metabolism , Scleroderma, Systemic/prevention & control , Signal Transduction/physiology , Adult , Animals , Bleomycin , Female , Fibroblasts/pathology , Fibrosis , Humans , Male , Mice , Middle Aged , Scleroderma, Systemic/pathology , Statistics, Nonparametric
13.
Arthritis Rheum ; 62(11): 3467-76, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20617520

ABSTRACT

OBJECTIVE: Cannabinoids are derivates of the marijuana component Δ(9) -tetrahydrocannabinol that exert their effects on mesenchymal cells and immune cells via CB1 and CB2 receptors. The aim of the present study was to evaluate the role of CB1 in systemic sclerosis. METHODS: CB1-deficient (CB1(-/-) ) mice and wild-type littermates (CB1(+/+) mice) were injected with bleomycin. CB1 signaling was activated in vivo with the selective agonist N-(2-chloroethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide (ACEA). Bone marrow transplantation experiments were performed to investigate whether the phenotype of CB1(-/-) mice was mediated by leukocytes or mesenchymal cells. The role of CB1 was also investigated in the TSK-1 mouse model. RESULTS: CB1(-/-) mice were protected from bleomycin-induced dermal fibrosis, with reduced dermal thickening, hydroxyproline content, and myofibroblast counts. Inactivation of CB1 decreased the number of infiltrating T cells and macrophages in lesional skin. In contrast, activation of CB1 with ACEA increased leukocyte infiltration and enhanced the fibrotic response to bleomycin. The phenotype of CB1(-/-) mice was mimicked by transplantation of CB1(-/-) mouse bone marrow into CB1(+/+) mice, demonstrating that CB1 exerts its profibrotic effects indirectly by regulating leukocyte infiltration. Consistently, knockdown of CB1 did not prevent fibrosis in the inflammation-independent TSK-1 mouse model. CONCLUSION: We demonstrate that the cannabinoid receptor CB1 is crucial for leukocyte infiltration and secondary fibroblast activation and that inactivation of CB1 exerts potent antifibrotic effects in inflammation-driven models of fibrosis.


Subject(s)
Inflammation/immunology , Neutrophil Infiltration/immunology , Receptor, Cannabinoid, CB1/immunology , Scleroderma, Systemic/immunology , Animals , Bone Marrow Transplantation , Fibrosis/genetics , Fibrosis/immunology , Fibrosis/metabolism , Immunohistochemistry , Inflammation/genetics , Inflammation/metabolism , Mice , Mice, Knockout , Receptor, Cannabinoid, CB1/genetics , Receptor, Cannabinoid, CB1/metabolism , Scleroderma, Systemic/genetics , Scleroderma, Systemic/metabolism , Statistics, Nonparametric
14.
Arthritis Res Ther ; 12(3): 125, 2010.
Article in English | MEDLINE | ID: mdl-20602813

ABSTRACT

Tissue fibrosis and vascular disease are hallmarks of systemic sclerosis (SSc). Transforming growth factor beta (TGFbeta) is a key-player in fibroblast activation and tissue fibrosis in SSc. In contrast to fibrosis, evidence for a role of TGFbeta in vascular disease of SSc is scarce. Using a transgenic mouse model with fibroblast-specific expression of a kinase-deficient TGFbeta receptor type II, Derrett-Smith and colleagues demonstrate that aberrant TGFbeta signaling in fibroblasts might result in activation of vascular smooth muscle cells and architectural changes of the vessel wall of the aorta.


Subject(s)
Fibroblasts/metabolism , Scleroderma, Systemic/metabolism , Signal Transduction/physiology , Transforming Growth Factor beta/metabolism , Vascular Diseases/metabolism , Animals , Aorta/metabolism , Aorta/pathology , Disease Models, Animal , Fibroblasts/pathology , Mice , Mice, Transgenic , Muscle, Smooth, Vascular/metabolism , Muscle, Smooth, Vascular/pathology , Protein Serine-Threonine Kinases/genetics , Protein Serine-Threonine Kinases/metabolism , Receptor, Transforming Growth Factor-beta Type II , Receptors, Transforming Growth Factor beta/genetics , Receptors, Transforming Growth Factor beta/metabolism , Scleroderma, Systemic/pathology , Vascular Diseases/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...